Finnish Brinter raises 1.2 million euros to accelerate bioscience research and manufacturing linked to 3D printing
3D printing, also known as additive manufacturing (AM), has gained increasing interest over the past decade and is used in many industries including construction, aerospace, food, and manufacturing. .
In recent years, 3D printing has sparked interest in medical and tissue engineering applications. This has led to significant advancements in the healthcare industry – 3D bioprinting, especially regenerative medicine which facilitates on-demand printing of cells, tissues and organs.
Here are the top ten international startups shortlisted for the Future Hamburg Award 2021
3D bioprinting is seen as an effective alternative to existing organ transplant methods due to continued demands and the lack of suitable organ donors.
According to various experts, research groups in several countries such as China, the United States, South Korea, the Netherlands and Singapore, among others, have invested heavily in the field of bioprinting.
Funding of â¬ 1.2 million raised
Turku-based bio-printing startup Brinter, a spin-off of 3DTech Ltd, is the latest company to receive funding. The Finnish startup has raised 1.2 million euros as part of the Seed Round led by VC Innovestor in the start-up phase.
The company will use the capital to further expand its international operations in Europe and the United States. It’s worth mentioning that Brinter has accelerated its growth since 2019 when it launched its first product.
Based in Helsinki, Innovestor is an early stage venture capital investor with a total of EUR 123 million spread over three funds.
The VC currently manages one of the largest private equity-funded portfolios in the Nordic countries, consisting of over 100 high-tech companies in multiple fields such as cleantech, consumer, enterprise software , health, industrial technologies and life sciences.
Bioprinting at your fingertips
Brinter is a modular multi-material bioprinting platform scalable from manual R&D to automated production. The company claims to be on a mission to bring bioprinting within the reach of every pharmaceutical company, hospital, university and research center.
The company provides 3D bioprinting solutions and services for the pharmaceutical, biotechnology and cosmetic industries, universities and research centers.
Brinter seeks to save more lives through more personalized treatment and the production of âspare partsâ such as hearts and kidneys.
We are delighted to have the support of Innovestor, which can help us accelerate the development of our operational capabilities and scale into new geographies, âsaid Tomi Kalpio, CEO of Brinter.
âBioprinting can quickly unlock the opportunities behind long-standing but unrealized science and research and plays a key role in pushing the boundaries of medical science. This will translate into improved quality of life for patients through the expansion of more personalized treatment and the continued development of bio-printed ‘spare parts’ that can save lives, âhe explains.
Brinter is active in more than ten countries and serves organizations such as Nanoform, as well as research organizations such as VTT, the BEST group at the University of Glasgow, the Johannes Gutenberg University in Mainz, the University of Oulu and the University of Helsinki.
Here’s how to build one that doesn’t work, according to this expert …